How Novo Nordisk is digitizing diabetes management

November 13, 2018 | Case Study

Novo Nordisk, a global leader in the diabetes space, has made several major announcements indicating its intent to digitize its diabetes management products. It just announced two new connected insulin pens to be launched in early 2019. It also announced an exclusive partnership with Flex Digital Health to manage its data infrastructure for its connected devices and nonexclusive technology partnerships with Dexcom, Glooko, and Roche to allow interoperability of their apps with the new insulin pens. These developments are timely and address an important need as more and more healthcare payers like Anthem, Cigna, Denver Health and EmblemHealth in the U.S. are calling for comprehensive digital diabetes prevention and management platforms.

Categories	Genomics, Mobile devices and wearables, Biochemical Medical Sensors, Clinical or Hospital Market, Consumer Health Market, Home-use Medical Devices, In Vitro Diagnostics (IVD), Minimally Invasive Medical Devices, Mobile Health (mHealth), Point-of-Care (POC), Artificial intelligence, Deep learning, Chemical Sensors, Health Sensors, Monitor and Tracking
Related companies	Novo Nordisk, Flex Ltd, Dexcom

About Lux Research

Lux Research is a leading provider of tech-enabled research and advisory solutions, helping clients drive growth through technology innovation. A pioneer in the research industry, Lux uniquely combines technical expertise and business insights with a proprietary intelligence platform, using advanced analytics and data science to surface true leading indicators. With quality data derived from primary research, fact-based analysis, and opinions that challenge traditional thinking, Lux clients are empowered to make more informed decisions today to ensure future success.

Already a Lux Client?

Interested in Learning More?

Or call us now

For North America (Boston Headquarters)
+1 (617) 502-5300

For EMEA (Amsterdam)
+31 20 280 7900

For APAC (Singapore)
+65 6592-6978